Interestingly, targeting the Th17-related cytokines pathways has been proposed; a recent randomized control clinical trial conducted in 118 patients failed to demonstrate the superiority of the anti-IL17 secukinumab in the treatment of uveitis in Behçet patients.[28] Nevertheless, blocking the IL17 axis could be important in the treatment of organ involvement other than ocular, and thus representing a novel promising treatment, at least for some disease phenotypes, such as the intestinal ones. The gene discussed is IL17A; the disease is uveitis.